The coinheritance of hypoplasminogenemia and heterozygous factor V deficiency in a relative with thrombotic disease and no hemorrhagic tendency is described. The proposita, a 28-year-old woman, suffered from neurologic disturbances due to two ischemic cerebral lesions confirmed by nuclear magnetic resonance scan. She was found to be affected with heterozygous plasminogen deficiency in a coagulation study for inherited thrombophilia. Moreover, she disclosed a prolongation of prothrombin time and activated partial thromboplastin time, which was compatible with heterozygous factor V deficiency. Her father, with a history of deep vein thrombosis, was also affected with plasminogen deficiency, as well as three brothers and one sister who were asymptomatic. The mother of the proposita showed borderline or slightly decreased factor V levels and normal plasminogen levels; she was therefore considered to be heterozygous for factor V deficiency.
Summary: The coinheritance of hypoplasminogenemia and heterozygous factor V deficiency in a relative with thrombotic disease and no hemorrhagic tendency is described. The proposita, a 28-year-old woman, suffered from neurologic disturbances due to two ischemic cerebral lesions confirmed by nuclear magnetic resonance scan. She was found to be affected with heterozygous plasminogen deficiency in a coagulation study for inherited thrombophilia. Moreover, she disclosed a prolongation of prothrombin time and activated partial thromboplastin time, which was compatible with heterozygous factor V deficiency. Her father, with a history of deep vein thrombosis, was also affected with plasminogen deficiency, as well as three brothers and one sister who were asymptomatic. The mother of the proposita showed borderline or slightly decreased factor V levels and normal plasminogen levels; she was therefore considered to be heterozygous for factor V deficiency.
Heterozygous factor V deficiency was also found in one brother and one sister of the proposita, and they were both asymptomatic. Among the other available family members, one brother and one sister of the proposita, all asymptomatic for either thrombotic or bleeding events, showed a normal clotting and fibrinolytic profile. To our knowledge, this is the first case of combined heterozygous plasminogen and factor V deficiency in the same family. Two of six patients with hypoplasminogenemia showed thrombotic events, and in one of these symptomatic cases the coexistence of factor V deficiency did not prevent the occurrence of thrombosis. As expected, no hemorrhagic tendency was observed in patients with heterozygous factor V deficiency, who may be mildly symptomatic only in 10% of cases. Key Words: Plasminogen deficiency&mdash;Factor V deficiency&mdash;Inherited clotting defects&mdash;Inherited thrombophilia.
Plasminogen is a 92 kD m.w. glycoprotein synthesized in the liver and present in plasma as an inactive proenzyme at a stable concentration of 1.6 ± 0.2 mM. To provide fibrin digestion, it is physiologically converted into the serine protease plasmin by the tissue-type and/or the urokinase-type plasminogen activators, tissue plasminogen activator (TPA) and urokinase plasminogen activator (UPA). An inadequate removal of intravascular fibrin deposition due to a defective fibrinolytic capacity may predispose to thrombosis. Congenital plasminogen defects are rare disorders described for the first time in 1978 as dysplasminogenemia (1) and in 1982 as hypoplasminogenemia (2) in patients with thromboembolic disease. Similarly to other congenital thrombophilic conditions, such as antithrombin III, protein C, protein S, and factor V Leiden defects, affected subjects usually develop thrombotic events at a young age, spontaneously or triggered by predisposing factors (trauma, surgery, plaster casts, etc.). The observed prevalence of thrombosis in patients with hypoplasminogenemia is lower than that found in patients with congenital defects of clotting inhibitors (3) . For this reason, the relationship between plasminogen defects and risk of thrombosis is still a matter of discussion (4) (5) (6) (7) (8) .
Factor V is a single-chain 330 kD m.w. glycoprotein synthesized in the liver and present in plasma at a concentration of 4-14 mg/L. It is also synthesized by megakariocytes and stored in platelet a-granules (9) . Its conversion into active cofactor is mediated by factor Xa and thrombin in the presence of phospholipids and calcium. Factor Va may accelerate prothrombin activation induced by factor Xa more than 350-fold. Activated protein C (APC) inactivates factor Va by producing several cleavages in its heavy-chain region, which consequently loses the capacity to bind factor Xa and prothrombin (9) .
Congenital factor V deficiency is a rare autosomal recessive bleeding disorder also known as parahemophilia (10) . Hemorrhagic manifestations usually develop in homozygous patients, even though the severity of bleeding symptoms may not always correlate with factor V plasma levels (11) . Reduced platelet content of factor V seems to have a better predictive value. Rare dysfunctional factor V defect and selective platelet factor V deficiency have been described in patients with a hemorrhagic tendency (12, 13) . Genetic analysis has recently identified a 4 bp deletion in exon 13 of the factor V gene in a family with type I quantitative factor V deficiency (14) . The mutation introduced a frameshift and a novel premature stop codon in codon 1303 causing the synthesis of a truncated factor V molecule and the lack of detectable factor V levels in plasma and platelets in patients homozygous for the mutant allele. Other point mutations in factor V gene may conversely determine a resistance to proteolysis by APC, thus facilitating the thrombus formation. Among these, the most frequent is the factor V Leiden mutation, which is characterized by an amino acid substitution at position 506 (Argso6 &horbar;G ln) and associated with enhanced thrombotic risk (15, 16) .
Factor V true deficiency has been described in association with other clotting factor abnormalities. Combined factor V and factor VIII deficiency is a wellknown congenital condition predisposing to hemorrhagic diathesis (17) (18) (19) (20) . In addition, the association between factor V and factor VII deficiency has been reported in a few families (21) . Moreover, pseudohomozygosity for APC resistance recently has been recognized as a combination of heterozygous factor V true deficiency and factor V Leiden mutation in patients with thrombotic tendency (22, 23) .
Combined defects of plasminogen and other thrombophilic conditions have been described, such as the association between plasminogen defects and protein C or protein S defects (8, 24, 25) . Moreover, a few unrelated kindreds with combined hypoplasminogenemia and factor V Leiden mutation recently have been described in a few families (8, (26) (27) (28) (29) .
In the present study, hypoplasminogenemia and heterozygous factor V true deficiency have been found to cosegregate in the same family.
CASE REPORT
The family pedigree is shown in Fig. 1 . The proposita (II-1), a 28-year-old woman, suffered from dizziness, vertigo, and left hemihypoesthesia of the face and tongue with ageusia in 1995. Two ischemic cerebral lesions, one in the left middle cerebellar peduncle (diameter, 8 mm) and the other in the right paraventricular region (diameter, 5 mm), were found on a nuclear magnetic resonance (NMR) scan. An electrocardiogram and a B-Mode echocardiogram were normal, thus excluding thromboembolism of the heart. The sensitivity deficit lasted about 1 year, whereas the disturbances of equilibrium disappeared within a few days. Her personal history was negative for bleeding tendency. She came to us for a laboratory screening of hereditary thrombophilia, which demonstrated a decrease of antigen and activity plasminogen levels to about 50% of normal, compatible with heterozygous plasminogen deficiency. Moreover, she disclosed a mild prolongation of both prothrombin time (PT) and activated partial thromboplastin time (aPTT), which was due to the coexistence of heterozygous factor V deficiency.
Among her available family members, her 67-year-old father (1-1) suffered from a deep vein thrombosis of the right leg after bone fracture in 1985. He was found heterozygous for plasminogen deficiency. The mother, five brothers, and three sisters of the proposita were asymptomatic for thrombotic or bleeding disorders.
METHODS
Blood samples were drawn between 8:00 and 10:00 AM after an overnight fast. A written informed consent was obtained from each subject before inclusion in the study. No patient was taking drugs affecting clotting and fibrinolytic tests at the time of the study. Eighteen milliliters of whole blood were drawn from an antecubital vein and mixed in a plastic syringe containing 2 mL of NaCitrate 0.13 M as an anticoagulant. After centrifugation for 15 minutes at 3000g, aliquots of separated platelet-poor plasma and buffy coat were stored at -30°C and tested within 1 month.
The following tests were carried out: PT, aPTT, Thrombotest and Normotest (Nycomed Pharma, Oslo, Norway), Hepato-Quick (Boehringer Mannheim, Milan, Italy), factor V activity (FV:act) and antigen (FV:Ag), fibrinogen, antithrombin III, protein C and protein S activities, APC sensitivity ratio (APC-SR), plasminogen activity (PLG:act) and antigen (PLG:Ag), antiphospholipids antibodies (APLA), lupus anticoagulant (LA), and genetic analysis for prothrombin variant 20210A.
Prothrombin, aPTT, and fibrinogen were performed by standard procedures. Thrombotest, Normotest, and Hepato-Quick were carried out using commercially available kits.
Factor V activity was assayed by a one-stage clotting method using factor V deficient plasma (Dade Laboratories, Miami, FL, USA) (30) . Factor V antigen was determined by an enzyme-linked immunosorbent assay (ELISA) method using polyclonal antifactor V antibodies (Inalco, Milan, Italy) (31). Protein C, protein S, and antithrombin III activity levels were carried out by chromogenic methods using commercially available kits (Berichrom PC, Behring, Scoppito, AQ, Italy; IL Protein S test, IL, Milan, Italy; Antithrombin III, Boehringer Mannheim, Germany; respectively) (32) . Activated protein C SR was performed on a ACL 3000 Plus (IL) as described by de Ronde and Bertina (33) .
Plasminogen activity was assayed by a chromogenic substrate method using streptokinase as activator (Berichrom PL [Behring]) (34) . Plasminogen antigen was carried out by means of the electroimmunoassay (Laurell) (35) using 1 % agarose in a sodium barbital buffer (pH 8.6) containing 1.2% antiplasminogen antiserum supplied by Behringwerke (Marburg, Germany).
The presence of APLA was tested for using Asserachrom APA (Boehringer Mannheim) as reported (36) . Lupus anticoagulant was assayed using commercially available kits for screening procedures (PTT-LA kit [Stago-Boehringer Mannheim, Milan, Italy] and Lupotest [Gradipore LTD, Pyrmont, Australia]) as previously described (37) .
Genomic DNA was extracted from blood by standard methods. Prothrombin variant 20210A was assessed as previously described (38) .
RESULTS
The results are shown in Tables 1 and 2 . The proposita (II-1 ), who was symptomatic for ischemic cerebral disease, showed a decrease of antigen and activity plasminogen levels (51 % and 53%, respectively) compatible with heterozygous plasminogen deficiency (Table 1) . Moreover, she disclosed a mild prolongation of PT and aPTT, whereas Thrombotest, Normotest, and Hepato-Quick were within normal ranges ( Table 2) . A parallel decrease of factor V antigen and activity levels to about 50% of normal, compatible with heterozygous factor V true deficiency, was detected (Table 1) . Fibrinogen, antithrombin III, protein C, and protein S levels, and APC-SR values were normal (Table 2) , as well as prothrombin genotype. Antiphospholipids antibodies and screening for LA were negative.
Hypoplasminogenemia was found in the symptomatic father (1-1), the three brothers (11-2, II-7, 11-8), and one sister of the index patient (Table 1 ). These subjects had a negative history for thrombotic events. Heterozygous factor V deficiency occurred in one 35-year-old sister (11-4) and one 33-year-old brother (11-9) of the TABLE 1. Plasma levels of plasminogen activity (Plg:act) and antigen (Plg:Ag) and of factor V activity (FV:act) and antigen (FV:Ag) in the proposita and in her available family members proposita ( Table 1 ). They were asymptomatic for bleeding tendency. The asymptomatic mother (1-2) showed borderline levels of factor V activity and decreased levels of factor V antigen (Table 1) , and she was assumed, on the basis of genetic considerations, to be heterozygous for factor V deficiency (Table 1 ). One brother (11-6) and one sister (11-3) of the proposita were normal for clotting and fibrinolytic tests, and they never experienced hemorrhagic or thrombotic manifestations.
DISCUSSION
Congenital heterozygous plasminogen deficiency is a rare fibrinolytic abnormality predisposing to thrombosis. The relationship between hypoplasminogenemia and thrombotic risk is a matter of debate (3) (4) (5) (6) (7) . Coinheritance of hypoplasminogenemia and other thrombophilic disorders, such as protein C, protein S, and APC resistance defects, has been reported (8, (26) (27) (28) (29) (30) (31) .
Hereditary defects of coagulation factor V are heterogeneous and on clinical grounds may be associated with hemorrhagic or thrombotic tendency. In this regard, an updated classification of factor V defects has been re- cently proposed (39) . Factor V true deficiency, also known as parahemophilia, is a rare recessive bleeding disorder where hemorrhagic manifestations are usually present in homozygous carriers even though not always correlated to the degree of defect (10) (11) (12) (13) . A 4 bp deletion in exon 13 of factor V gene has been recently identified as a genetic abnormality causing parahemophilia (14) . Combined factor V and factor VIII deficiency is a well-known bleeding defect further classified in type I and type II on the basis of hereditary transmission and factor V activity levels (39) . In rare instances the association of factor V and factor VII deficiency has been reported (21) . Finally, the coinheritance of heterozygous factor V deficiency and heterozygous factor V Leiden defect, the so-called pseudohomozygosity for APC resistance, has been described in a few cases with thrombotic diathesis (22, 23) . The phenotypic picture resembles homozygotes for APC resistance.
This article describes the first family with a combined defect of heterozygous factor V true deficiency and hypoplasminogenemia.
No hemorrhagic tendency was observed in our patients with factor V deficiency. This finding agrees with the literature and our personal experience. In fact, heterozygous factor V deficiency carriers are usually asymptomatic, even though mild bleeding tendency may occur in about 10% of cases (39) . This could explain why the actual incidence of this clotting disorder is not well known and may be underestimated.
Because factor V levels were borderline or slightly decreased in the mother, we surmise that she was the carrier. This observation could be explained by a possible increase of factor V levels with age, as may occur for other clotting factors. Moreover, this has been demonstrated to be the case for factor II and factor X (40, 41) . Only genetic studies could answer the question.
The presence of factor V deficiency in the patient with hypoplasminogenemia did not eliminate the thrombotic risk. A similar clinical effect has been observed in patients with pseudohomozygosity for APC resistance, where the absence of half the amount of normal factor V seems unable to modify the thrombotic tendency due to the presence of half factor V Leiden. In actuality, patients with pseudohomozygosity have a thrombotic tendency similar to that presented by homozygous patients. In vitro studies recently have shown that the inactivation of factors VIII and Villa by APC in the presence of protein S is enhanced by factor V, namely by fragments derived from the B region of factor V (42, 43) . Moreover, factor V Leiden was much less effective as a cofactor in APC-mediated factor VIII inactivation, suggesting a further contribution to the increased risk for thrombosis in APC-resistant individuals (44) . These findings might partly explain in vivo not only the lack of bleeding ten-dency, but also the lack of protection against thrombosis in heterozygous factor V deficient patients.
The coinheritance of both a prothrombotic defect and a bleeding disorder has been described in a family with combined antithrombin III abnormality (AT III Trento) and von Willebrand factor deficiency (45) . However, in this instance, the presence of von Willebrand disease appeared to play a protective role towards thrombotic risk due to the antithrombin III defect.
In the family we studied, two (33.3%) of six patients with hypoplasminogenemia suffered from thrombotic events. These findings support the opinion that congenital plasminogen abnormalities may be associated with thrombotic risk, although to a lesser extent than carriers of clotting inhibitor defects.
